Amicus Therapeutics — Q2 2021 Earnings Presentation
23 slides from Amicus Therapeutics's earnings presentation, Aug 5, 2021
Slide 1: 2Q21 Financial Results Conference Call & Webcast
2Q21 Financial Results Conference Call & Webcast August 5, 2021
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements Introduction This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinica
Slide 3: A leading fully integrated, global rare disease biotechnology company
3 A leading fully integrated, global rare disease biotechnology company Introduction Gene Therapy PLATFORM Protein Engineering & Glycobiology $383M Cash as of 6/30/21 Two Clinical- Stage Gene Therapies AT-GAA Registration in Pompe Disease GLOBAL COMMERCIAL ORGANIZATION World Class BIOLOGICS Capabili
Slide 4: 2021 Key Strategic Priorities
4 2021 Key Strategic Priorities Introduction 1 2 3 4 5 Achieve double-digit Galafold growth and revenue of $300M to $315M Report data from the AT-GAA Phase 3 PROPEL study and complete BLA and MAA filings for regulatory approvals Advance clinical studies, regulatory discussions and scientific data ac
Slide 5: Galafold (migalastat) Global Launch
Galafold® (migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement
Slide 6: Galafold Snapshot (as of June 30, 2021)
6 Galafold Snapshot (as of June 30, 2021) Galafold: Precision Medicine for Fabry Disease One of the Most Successful Rare Disease Launches 348 Amenable Variants in U.S. Label 40+ Countries with Regulatory Approvals: including U.S., EU, Japan and other Countries Continued Expansion in 2021 $77.4M +24%
Slide 7: Galafold Success and FY21 Revenue Guidance
7 Galafold Success and FY21 Revenue Guidance Galafold momentum remains on track to achieve full year 2021 revenue guidance Galafold: Precision Medicine for Fabry Disease FY16 FY17 FY18 FY19 FY20 FY21 $36.9M $91.2M $260.9M FY21 Rev. Guidance $300M-$315M $182.2M $5.0M Q1 $66.4M Q2 $77.4M H1 $143.8M
Slide 8: Outlook for 2021
8 Outlook for 2021 • Global demand remains strong with 1H21 revenue growth rate of 17% and continued growth anticipated in 2021 and beyond • Net new international patients in June was the second-best month since launch • In 2021, project double-digit revenue growth with net new patient starts expect
Slide 9: Galafold Opportunity
9 $91M ~$500M Projected Revenue Galafold Opportunity Galafold: Precision Medicine for Fabry Disease With inherent Fabry market growth and our work to improve screening and diagnosis, Galafold has the potential to drive $1B+ annual revenue at peak $1B+ Opportunity Durable growth and increasing invest
Slide 10: AT-GAA: Next Potential Standard of Care for Pompe Disease
AT-GAA: Next Potential Standard of Care for Pompe Disease “We encourage and embrace constant innovation” - Amicus Belief Statement
Slide 11: Pompe Disease Overview
11 Pompe Disease Overview Pompe disease is a severe and fatal neuromuscular disease and one of the most prevalent lysosomal disorders with very high unmet medical need AT-GAA for Pompe Disease Deficiency of GAA leading to glycogen accumulation and cellular dysfunction Age of onset ranges from infanc
Slide 12: PROPEL Study Primary, Key Secondary and Biomarker Endpoint Heat Map
12 Phase 3 PROPEL Study Primary, Key Secondary and Biomarker Endpoint Heat Map AT-GAA for Pompe Disease Endpoints across motor function, pulmonary function, muscle strength, PROs and biomarkers favored AT-GAA over alglucosidase alfa in both the overall and ERT experienced populations Source: Present
Slide 13: AT-GAA: Next Steps
13 AT-GAA: Next Steps AT-GAA for Pompe Disease AT-GAA for Pompe Advances Toward Approval • Completed rolling BLA and NDA submissions to the U.S. FDA • Positive EMA rapporteur and co-rapporteur meeting supportive of MAA submissions • Granted positive scientific opinion through the Early Access to Med
Slide 14: Next Generation Gene Therapy Platform
“We have a duty to obsolete our own technologies” - Amicus Belief Statement Next Generation Gene Therapy Platform
Slide 15: Next Generation Gene Therapy Platform Pipeline
15 Next Generation Gene Therapy Platform *Exclusive license from Ultragenyx for Japanese rights to Mepsevii™, investigator-sponsored trial in Japan underway DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold®(migalastat) Monotherapy Fabry Gene Therapy PENN Pompe F
Slide 16: Amicus Protein Engineering Expertise & Technologies for Gene Therapy
16 Amicus Protein Engineering Expertise & Technologies for Gene Therapy Next Generation Gene Therapy Platform Differentiated gene therapy approach for greater potency and optimized cross correction through transgene engineering for stability and targeting .. Proprietary AAV capsid .. Pantropic capsi
Slide 17: Financial Summary
“We are business led and science driven” - Amicus Belief Statement Financial Summary
Slide 18: 2Q21 Select Financial Results
18 2Q21 Select Financial Results Financial Summary Jun. 30, 2021 (in thousands, except per share data) Jun. 30, 2020 Product Revenue $77,413 62,353 Cost of Goods Sold 8,380 6,676 R&D Expense 63,003 69,611 SG&A Expense 42,276 34,657 Changes in Fair Value of Contingent Consideration 1,021 715 Deprecia
Slide 19: Financial Outlook: Key Takeaways
19 Financial Outlook: Key Takeaways • Reaffirming full-year Galafold revenue guidance of $300 million to $315 million • Non-GAAP operating expense guidance for 2021 is expected to remain flat at $410 million to $420 million – Driven by disciplined expense management and continued investment in the g
Slide 20: Closing Remarks
Closing Remarks “We believe in our future to build long-term value for our stakeholders” - Amicus Belief Statement
Slide 21: Thank You
Thank You “Our passion for making a difference unites us” -Amicus Belief Statement
Slide 22: Appendix
Appendix Amicus Therapeutics
Slide 23: Reconciliation of Non-GAAP Financial Measures
Appendix Reconciliation Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Total operating expenses - as reported GAAP $107,867 $107,022 $220,785 $239,052 Research and development: Share-bas